Equities

Chongqing Taiji Industry Group Co Ltd

600129:SHH

Chongqing Taiji Industry Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)33.88
  • Today's Change-0.35 / -1.02%
  • Shares traded16.65m
  • 1 Year change-10.08%
  • Beta1.2125
Data delayed at least 15 minutes, as of Mar 28 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CHONGQING TAIJI INDUSTRY (GROUP) CO., LTD. is a China-based company principally engaged in the production and sales of Chinese and Western medicines. The Company is also engaged in the cultivation of medicinal herbs. The Company's products mainly include capsules, syrup, oral liquid, lyophilized series, tablets, infusion series and injections. The Company mainly conducts its business in domestic and overseas markets.

  • Revenue in CNY (TTM)15.69bn
  • Net income in CNY858.90m
  • Incorporated1993
  • Employees19.70k
  • Location
    Chongqing Taiji Industry Group Co LtdNo.18Hengshan East Road, Yubei DistrictCHONGQING 401121ChinaCHN
  • Phone+86 2 389886129
  • Fax+86 2 389887399
  • Websitehttp://www.taiji.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Anhui Huaheng Biotechnology Co Ltd1.80bn422.94m17.85bn995.0042.0410.46--9.922.702.7011.4710.840.78157.719.641,808,077.0018.3217.8624.0422.2939.6638.6723.4421.490.7354--0.270919.3948.6929.9790.2337.5956.88--
Nanjing King-Frind Bchmcl Phrmctcl C Ltd4.00bn1.02bn17.93bn1.40k17.482.62--4.480.63460.63462.484.230.38130.36924.832,867,937.009.7212.9314.4918.9649.0053.8725.5027.461.02--0.32420.300.70627.252.9828.2642.1023.27
Sinocelltech Group Ltd1.75bn-336.34m18.03bn1.87k------10.29-0.7593-0.75933.95-0.97260.70630.37886.48937,947.60-13.58-56.05-37.26-89.6596.3096.27-19.23-288.840.47810.85411.19--661.33179.5540.13--51.77--
Dizal Jiangsu Pharmaceutical Co Ltd40.10m-1.05bn18.04bn328.00--16.37--449.94-2.59-2.590.09842.650.0204--1.52122,263.40-53.53---66.24--93.97---2,630.41--2.02--0.202---100.00---9.87------
Shandong Buchang Pharmaceuticals Co Ltd13.63bn-1.87bn18.24bn8.49k--1.49--1.34-1.69-1.6912.3211.050.60871.129.711,605,200.00-8.864.93-12.077.0569.2577.42-14.567.180.5054-20.160.2163109.43-5.151.52-218.65---17.890.1039
Changchun BCHT Biotechnology Co1.82bn501.01m18.33bn1.24k36.594.56--10.051.211.214.429.740.39120.9781.441,470,338.0010.749.9513.1912.8189.5286.6327.4624.032.02--0.005110.5570.3012.36175.9831.3721.04--
Zhejiang Huahai Pharmaceutical Co., Ltd.8.64bn1.09bn18.95bn7.68k16.892.29--2.190.75690.75695.995.570.48891.033.471,124,103.006.145.418.377.9359.5060.4512.5610.640.87956.700.47532.1224.4210.57139.5212.8123.869.63
Chongqing Taiji Industry Group Co Ltd15.69bn858.90m19.06bn19.70k22.195.00--1.211.541.5428.176.851.143.546.061,235,024.006.25-0.366818.00-1.0947.2942.205.50-0.41490.5286.780.5483--15.659.88166.8429.041.80--
Tonghua Dongbao Pharmaceutical Co Ltd2.77bn939.27m19.72bn3.05k21.002.89--7.120.4710.4711.393.430.39340.93695.38907,297.1013.3418.9314.1920.1077.5277.2533.9137.964.69--0.021542.62-14.981.7720.9213.5921.5924.57
Joincare Pharmaceutical Group Ind. Co.16.78bn1.46bn20.33bn14.12k14.331.52--1.210.76070.76078.757.190.47622.675.341,188,867.008.348.2216.9218.8760.0863.1417.5016.342.29--0.249232.277.799.7213.10-6.7719.021.96
Shanghai Allist Pharmaceuticals Co Ltd1.62bn487.02m20.84bn870.0042.795.71--12.861.081.083.608.100.45131.969.771,863,318.0013.56-6.7014.46-7.3894.9496.6330.04-49.488.50--0.0006--49.22152.37614.22--152.72--
China Resources Dubl-Crne Phrmctl Co Ltd10.22bn1.33bn21.00bn12.27k15.541.87--2.051.301.309.9810.830.66822.727.04833,167.508.678.5811.5911.2153.9458.1912.9711.981.92--0.027935.916.204.4412.966.6021.46-1.63
Data as of Mar 28 2024. Currency figures normalised to Chongqing Taiji Industry Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

20.82%Per cent of shares held by top holders
HolderShares% Held
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 202330.65m5.50%
Zhong Ou Asset Management Co., Ltdas of 30 Sep 202318.62m3.34%
Huashang Fund Management Co., Ltd.as of 30 Jun 202313.36m2.40%
Bosera Asset Management Co., Ltd.as of 30 Jun 202313.05m2.34%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 202310.75m1.93%
GF Fund Management Co., Ltd.as of 30 Sep 20238.96m1.61%
Cinda Fund Management Co. Ltd.as of 30 Jun 20235.88m1.06%
China Asset Management Co., Ltd.as of 31 Dec 20235.41m0.97%
China Universal Asset Management Co., Ltd.as of 30 Jun 20234.95m0.89%
Minsheng Royal Fund Management Co., Ltd.as of 30 Jun 20234.31m0.77%
More ▼
Data from 30 Jun 2023 - 21 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.